We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+91.23%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$18.1M
Cap. Flow
+$54.1M
Cap. Flow %
7.36%
Top 10 Hldgs %
42.08%
Holding
212
New
67
Increased
34
Reduced
65
Closed
41

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$11.6M
2
TGTX icon
TG Therapeutics
TGTX
+$8.36M
3
BPMC
Blueprint Medicines
BPMC
+$7.73M
4
FBRX icon
Forte Biosciences
FBRX
+$7.25M
5
VIR icon
Vir Biotechnology
VIR
+$7.08M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$19.2M
2
ONC
BeOne Medicines Ltd
ONC
+$18M
3
SLNO
Soleno Therapeutics
SLNO
+$11.5M
4
RCUS icon
Arcus Biosciences
RCUS
+$5.97M
5
TECX
Tectonic Therapeutic
TECX
+$5.28M

Sector Composition

Rank Sector Weight
1 Healthcare 47.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
101
PUT
Altimmune
ALT
$552M
$1.19M 0.16%
+165,700
New +$1.27M
JSPR icon
102
Jasper Therapeutics
JSPR
$21M
$1.18M 0.16%
55,107
-68
-0.1% -$1.42K
ALLK
103
DELISTED
Allakos
ALLK
$1.18M 0.16%
971,950
-725
-0.1% -$761
LXRX icon
104
Lexicon Pharmaceuticals
LXRX
$1.03B
$1.14M 0.16%
+1,550,000
New +$1.87M
MIST icon
105
Milestone Pharmaceuticals
MIST
$138M
$1.1M 0.15%
466,030
+11
+0% +$19
SANA icon
106
CALL
Sana Biotechnology
SANA
$871M
$1.06M 0.14%
650,000
– –
THRD
107
DELISTED
Third Harmonic Bio
THRD
$1.03M 0.14%
+100,000
New +$1.25M
VERV
108
DELISTED
Verve Therapeutics
VERV
$959K 0.13%
169,991
-9
-0% -$51
PYXS icon
109
Pyxis Oncology
PYXS
$168M
$957K 0.13%
613,253
-344,155
-36% -$993K
FULC icon
110
Fulcrum Therapeutics
FULC
$273M
$940K 0.13%
200,096
+125,096
+167% +$462K
RNAC icon
111
Cartesian Therapeutics
RNAC
$229M
$934K 0.13%
52,166
-27
-0.1% -$547
TRAW icon
112
Traws Pharma
TRAW
$6.85M
$875K 0.12%
+98,493
New +$548K
ACRS icon
113
Aclaris Therapeutics
ACRS
$726M
$868K 0.12%
+350,000
New +$871K
VIGL
114
DELISTED
Vigil Neuroscience
VIGL
$850K 0.12%
+500,000
New +$1.48M
TYRA icon
115
Tyra Biosciences
TYRA
$1.9B
$834K 0.11%
+60,000
New +$1.09M
LYEL icon
116
Lyell Immunopharma
LYEL
$317M
$817K 0.11%
63,802
+37,499
+143% +$743K
SANA icon
117
PUT
Sana Biotechnology
SANA
$871M
$815K 0.11%
500,000
-150,000
-23% -$447K
CMPS
118
Compass Pathways
CMPS
$1.53B
$767K 0.1%
202,894
-14
-0% -$71
AMLX icon
119
Amylyx Pharmaceuticals
AMLX
$2.26B
$760K 0.1%
201,187
-73,364
-27% -$345K
KZR
120
DELISTED
Kezar Life Sciences
KZR
$718K 0.1%
106,901
+2
+0% +$15
NRIX icon
121
Nurix Therapeutics
NRIX
$2.41B
$659K 0.09%
34,985
-225,015
-87% -$5.16M
PHGE icon
122
BiomX
PHGE
$1.99M
$652K 0.09%
46,999
-1
-0% -$14
INBX icon
123
Inhibrx
INBX
$1.2B
$649K 0.09%
42,122
-1
-0% -$15
AEMD icon
124
Aethlon Medical
AEMD
$1.75M
$645K 0.09%
+9,375
New +$318K
IMUX icon
125
CALL
Immunic
IMUX
$190M
$636K 0.09%
+63,580
New +$801K
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Ikarian Capital held 212 positions worth $735M, up 2.5% from $717M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital deployed $54.1M of net new capital in Q4 2024, opening 67 new positions and adding to 34 existing holdings. Its largest new stake was Scholar Rock: 357,185 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $19.2M trimmed.

  • Ikarian Capital's largest Q4 2024 buy was Scholar Rock: 357,185 shares worth $15.4M.
  • Ikarian Capital added most to Blueprint Medicines in Q4 2024, an estimated $7.73M increase.
  • Ikarian Capital's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $19.2M.
  • Ikarian Capital fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $18M.
  • Ikarian Capital's ten largest holdings make up 42% of its $735M portfolio in Q4 2024.
  • Ikarian Capital opened 67 new positions and closed 41 in Q4 2024.
  • Ikarian Capital's portfolio value rose 2.5% quarter-over-quarter to $735M.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.